Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2008-07-11
2010-02-09
Salimi, Ali R. (Department: 1648)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
Reexamination Certificate
active
07659071
ABSTRACT:
The present invention concerns the use of E6 and/or E7 peptides from human papilloma virus (HPV) to evaluate a cell-mediated response in a patient infected with HPV to determine the prognosis for that patient with respect to the development or recurrence of pre-cancerous or cancerous growths, including cervical intraepithelial neoplasia (CIN).
REFERENCES:
patent: 5665535 (1997-09-01), Orth et al.
patent: 5876922 (1999-03-01), Orth et al.
patent: 6135965 (2000-10-01), Tumer et al.
patent: 6258576 (2001-07-01), Richards-Kortum et al.
patent: 0 402 132 (1990-06-01), None
patent: 0 520 994 (1995-01-01), None
Japanese Office Action, issued in Japanese Application No. 2003-514964, dated Nov. 7, 2008.
Seedorf et al., “Human Papillomavirus Type 18 DNA Sequence,”Virology, 145:181-185, 1985.
Aichele et al., “Antiviral cytotoxic T cell response induced by in vivo priming with a free synthetic peptide,”J. Exp. Med., 171(5):1815-1820, 1990.
Borysiewicz et al., “A recombinant vaccina virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer,”Lancet, 347:1523-1527, 1996.
Casement et al., “Cross-reactive cytotoxic T lymphocytes induced by V3 loop synthetic peptides from different strains of human immunodeficiency virus type 1,”Virology, 211(1):261-267, 1995.
Cason et al., “Detection of antibodies to a linear epitope on the major coat protein (L1) of human papillomavirus type-16 (HPV-16) in sera from patients with cervical intraepithelial neoplasia and children,”Int. J. Cancer, 50:349-355, 1992.
Chen et al., “Induction of cytotoxic T lymphocytes specific for a syngeneic tumor expressing the E6 oncoprotein of human papillomavirus type 16,”J Immunol., 148(8):2617-2621, 1992.
Clavel et al., “Human papillovirus detection by the hybrid capture II assay: a reliable test to select women with normal cervical smears at risk for developing cervical lesions,”Diagn. Mol. Pathol., 9(3):145-150, 2000.
Clerici et al., “Cytokine production patterns in cervical intraepithelial neoplasia: association with human papillomavirus infection,”J. Natl. Cancer Inst., 89(3):245-250, 1997.
de Gruijil et al., “T cell proliferative responses against human papillomavirus type 16 E7 oncoprotein are most prominent in cervical intraepithelial neoplasia patients with a persistent viral infection ,”J Gen Virol., (Pt 9):2183-91. 1996.
Deres et al., “In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine,”Nature, 342(6249):561-564, 1989.
Dillner et al., “Mapping of linear epitopes of human papillomavirus type 16 the L1 and L2 open reading framed,”Int. J. Cancer, 45:529-535, 1990.
Feltkamp et al., “Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells,”Eur. J. Immunol., 23:2242-2249, 1993.
Fischer et al., “The association of human papillomavirus type 16 E6 and E7 antibodies with stage of cervical cancer,”Gynecologic Oncology, 61, No. 0099, 73-78, 1996.
Hamsikova et al., “Presence of antibodies to seven human papillomavirus type 16-derived peptides in cervical cancer patients and healthy controls,”J. Infect. Dis., 170:1424-1431, 1994.
Jha et al., “Antibodies to human papillomavirus and to other genital infectious agents and invasive cervical cancer risk,”Lancet, 341:1116-1118, 1993.
Kadish et al., “Lymphoproliferative responses to human papillomavirus (HPV) type 16 proteins E6 and E7: outcome of HPV infection and associated neoplasia,”J. Natl. Cancer Inst., 89:1285-1293, 1997.
Kast et al., “Human leukocyte antigen-A2.1 restricted candidate cytotoxic T lymphocyte epitopes of human papillomavirus type 16 E6 and E7 proteins identified by using the processing-defective human cell line T2,”J. Immunotherapy, 14:115-120, 1993.
Kast et al., “In vivo efficacy of virus-derived peptides and virus-specific cytotoxic T lymphocytes,”Immunol Lett., 30(2):229-232, 1991.
Lorenzato et al., “DNA image cytometry and human papillomavirus (HPV) detection help to select smears at high risk of high-grade cervical lesions,”J. Pathol., 194(2):171-176, 2001.
Müller et al., “Identification of seroreactive regions of the human papillomavirus type 16 proteins E4, E6, E7 and L1,”Journal of General Virology, 71:2709-2717, 1990.
Munger et al., “The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes,”J. Virol., 63:4417-4421, 1989.
Nakagawa et al., “Cytotoxic T lymphocyte responses to E6 and E7 proteins of human papillomavirus type 16: relationship to cervical intraepithelial neoplasia,”J. Infect. Dis., 175:927-931, 1997.
Nakagawa et al., “T-cell proliferative responses to human papillomavirus type 16 peptides: relationship to cervical intraepithelial neoplasia,”Clin. Diag. Lab. Immunol., 3(2):205-210, 1996.
Nehete et al., “Cross-reactive T-cell proliferative responses to V3 peptides corresponding to different geographical HIV-1 isolates in HIV-seropositive individuals,”J. Clin. Immunol., 16(2):115-124, 1996.
Nindl et al., “Antibodies against linear and conformational epitopes of the human papillomavirus (HPV) type 16 E6 and E7 oncoproteins in sera of cervical cancer patients,”Archives of Virology, 137:341-353, 1994.
Office Communication, mail date Feb. 5, 2007.
Office Communication, mail date Jun. 4, 2007.
Park et al., “Cell-mediated immunity in cervical intraepithelial neoplasia,”Asia-Oceania J. Obstet. Gynaecol., 18:171-175, 1992.
Poljak et al., “Comparative evaluation of first- and second-generation digene hybrid capture assays for detection of human papillomaviruses associated with high or intermediate risk for cervical cancer,”J. Clin. Microbiol., 37(3):796-797, 1999.
Ressing et al., “Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicigy studies of HLA-A *0201-binding peptides,”J. Immunology, 154:5934-5943, 1995.
Ressing et al., “Occasional memory cytotoxic T-cell responses of patients with human papillomavirus type 16-positive cervical lesions against a human leukocyte antigen-A *0201-restricted E7-encoded epitome,”Cancer Res., 56:582-588, 1996.
Rochlitz et al., “Mutations in the ras protooncogenes are rare events in renal cell cancer,”Eur. J. Cancer, 28(2/3):333-336, 1992.
Sarkar et al., “Studies on in vivo induction of cytotoxic T lymphocyte responses by synthetic peptides from E6 and E7 oncoproteins of human papillomavirus type 16,”Viral Immunol., 8(3):165-174, 1995.
Sasagawa et al., “Identification of antibodies against human papillomavirus type 16 E6 and E7 proteins in sera of patients with cervical neoplasias,”Japanese Journal of Cancer Research, 83:705-713, 1992.
Sastry et al., “Effects of influenza virus-specific cytotoxic T-lymphocyte responses induced induced by a synthetic nucleoprotein peptide on the survival of mice challenged with a lethal dose of virus,”Vaccine, 12(14):1281-1287, 1994.
Sastry et al., “Rapid in vivo induction of HIV-specific CD8+ cytotoxic T lymphocytes by a 15-amino acid unmodified free peptide from the immunodominant V3-loop of GP120,”Virology, 188:502-509, 1992.
Schiffman et al., “Accuracy and interlaboratory reliability of human papillomavirus DNA testing by hybrid capture,”J. Clin. Microbiology, 33(3):545-550, 1995.
Seedorf et al., “Identification of early proteins of the human papilloma viruses type 16 (HPV 16) and type 18 (HPV 18) in cervical carcinoma cells,”EMBO J., 6(1):139-144, 1987.
Sehr et al., “A generic capture ELISA for recombinant proteins fuse dto glutathione S-transf
Follen Michele
Sastry Jagannadha K.
Tortolero-Luna Guillermo
Board of Regents the University of Texas System
Fulbright & Jaworski LLP
Salimi Ali R.
LandOfFree
Methods and compositions relating to HPV-associated... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions relating to HPV-associated..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions relating to HPV-associated... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4196139